Results demonstrated that a once daily oral treatment of PBI-1402 induces a significant increase in hemoglobin level, red blood cell (RBC) count and hematocrit in chemotherapy-induced anemia (CIA) patients.
Furthermore, results suggest that PBI-1402 can reduce the need for RBC transfusion, since only 6% of patients in the clinical trial required transfusion.
Pierre Laurin, president and CEO of ProMetic, said: “This data further supports that PBI-1402’s current performance is in line with the FDA’s recommendation of reducing patient need for RBC transfusions.”